|
|
|
|
 |
Sequenom and SensiGen Expand Global Alliance |
| Companies mentioned in this article: |
|
Sequenom, Inc. |
|
| 7/30/2008 @ 4:55 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Sequenom, Inc. (NASDAQ: SQNM), a leading provider of molecular diagnostic applications and genetic analysis products and services, and SensiGen LLC, a privately held biotechnology company focused on developing proprietary gene-based, molecular diagnostic tests, today announced expansion of their global alliance to develop and market advanced diagnostic tests and systems to commercial laboratories worldwide. Under the expanded agreement, in addition to commercializing SensiGen’s advanced test for human papillomavirus (HPV) exclusively on Sequenom’s MassARRAY platform, SensiGen will also be the exclusive provider of MassARRAY platform-based assays for SensiGen’s newly developed Chronic Kidney Disease (CKD) and Lupus tests. Sequenom will exclusively supply platform technology and reagents used for commercializing SensiGen’s proprietary tests. The expanded agreement also provides Sequenom with the future right to a minority equity interest in SensiGen. Financial terms of the alliance were not disclosed.
“SensiGen’s portfolio of advanced diagnostic tests is complementary to the proprietary portfolio of diagnostic tests that Sequenom is building, especially in the area of women’s health,” said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. “We believe this expanded alliance with SensiGen will enable us to offer a broader menu of MassARRAY platform-based products and services that meet the needs of clinical laboratory customers and provide significant value in the global healthcare marketplace.”
SensiGen’s AttoSense assays are capable of accurately identifying minute quantities – in some cases a single copy – of the biomarkers associated with the onset of major diseases or the pathogens that cause them. SensiGen’s assays are designed to take advantage of the high sensitivity and specificity of the MassARRAY system by coupling SensiGen’s state-of-the-art polymerase chain-reaction (PCR) methodology, with its proprietary sample preparation methods, primers and markers, to achieve unprecedented results. Because the mass of a biological substance is highly specific, this technique is well-suited for identifying nucleic acids that are difficult to detect accurately by current hybridization methods and / or are found in extremely small quantities.
“We now have a growing database of results from numerous customer-evaluation and benchmarking studies that demonstrate the superiority of the AttoSense / MassARRAY technology method compared to conventional hybridization methods in terms of both technical quality, as well as throughput and cost-per-test,” said Shawn M. Marcell, President and Chief Executive Officer of SensiGen. “No other platform can deliver the level of precision and accuracy that our AttoSense assays achieve on the MassARRAY system. We are pleased to expand our relationship with Sequenom and are eager to accelerate our development and joint marketing efforts in the months ahead.”
About Human Papillomavirus (HPV)
In the United States, more than 55 million women are screened each year for cervical cancer at a cost of more than $2 billion. Despite screening, 9,000 new cases and 4,000 deaths from cervical cancer are reported annually, due in part to the limitations of currently available tests. In addition to the well-known Pap test, more than 7 million HPV DNA tests are conducted annually worldwide, and the total number of HPV DNA tests is growing at a rate exceeding 35% per year.
SensiGen’s proprietary AttoSense HPV test is a highly sensitive (98%+), specific (99%+), multiplex assay that in one step identifies the presence and quantity of all known HPV oncogenic types. The extreme accuracy versus conventional methods, attractive economics and ease of integration into current laboratory practice offered by the AttoSense HPV test provide competitive advantages and significant worldwide market potential. This assay is in late-stage development and clinical trials are expected to begin in late 2008.
About Chronic Kidney Disease (CKD)
Approximately 20 million Americans have some evidence of CKD and another 20 million are at risk for developing this disease. High-risk groups for which annual screening would be indicated include Type I or Type II diabetes patients, hypertensives, and patients with systemic Lupus erythematosus (SLE). In the U.S., $450 million is spent annually on kidney disease testing primarily via the micro albumin test, which only detects later stages of the disease (Stage 3 and beyond), at a time when treatment options are far less effective.
SensiGen’s proprietary AttoSense Kidney test detects a specific gene product uniquely associated with the onset of pathological processes that lead to CKD (i.e., in Stages 1 & 2 of the disease). Current testing modalities are unable to detect these processes before Stage 3, at which point extensive and irreversible kidney damage has occurred. When detected early, available treatments for CKD can arrest or significantly delay disease progression. The AttoSense Kidney Test is in late-stage development and clinical trials are expected to begin in late 2008 or early 2009.
About Lupus
Systemic Lupus erythemetosis (SLE) is a widespread and chronic autoimmune disease in which an individual’s immune system attacks the body’s own tissues and organs. An estimated 1.5 million Americans, mainly women, are currently afflicted with Lupus and 16,000 new cases are diagnosed annually. Symptoms of Lupus include extreme fatigue, painful and swollen joints, fever, skin rashes and deterioration of kidney function. The root cause of this disease is unknown, and there is no known cure. If detected sufficiently early, treatments are available to help patients manage the disease and reduce the impact of periodic episodes or symptom flare-ups common to Lupus.
SensiGen is developing a test for a set of proprietary epigenetic biomarkers that have been shown to be uniquely associated with the onset and severity of Lupus. The role of epigenetics in the etiology of human diseases is becoming increasingly recognized, making it among the fastest growing fields of genetic research today. Tests for epigenetic biomarkers must accurately distinguish between subtle differences in genetic codes and must also measure the precise ratio of their quantities. SensiGen is developing an AttoSense multiplex assay for these new epigenetic biomarkers and data obtained from initial studies is promising.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular medicine applications, and for research conducted in the agro (agricultural and livestock) industry. The Company’s proprietary MassARRAY system is a high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms.
About SensiGen LLC
SensiGen is a biotechnology company focused on gene-based molecular diagnostics. The Company develops advanced high value diagnostic tests to enable early detection of diseases, aimed at improving standards of care and reducing overall health care costs. Current products in development include tests for early detection of human papillomavirus (HPV), the primary cause of cervical cancer, Chronic Kidney Disease (CKD), Lupus, and others. SensiGen’s proprietary molecular diagnostic assays offer dramatic improvements over current methods. Additional information is available at www.sensigen.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
